Real 2026 valuation guidance, why prescription volume and payer mix are everything, and how to get a free, confidential valuation.
Independent pharmacies typically sell for 3x to 4x annual EBITDA, reflecting thinner 10-15% profit margins compared to other retail categories. Monthly prescription volume and payer mix are the two biggest factors driving where you land in that range.
These figures are industry rules of thumb, not appraisals — your actual valuation could land higher or lower than shown above depending on your specific script volume, payer mix, and inventory.
A shrinking prescription count signals future revenue risk that buyers price directly into a lower offer.
A pharmacy weighted heavily toward lower-reimbursement plans generates less value per prescription.
New chain pharmacy competition nearby is a real risk buyers will ask about and price into their offer.
Independent pharmacies are typically valued around 3x to 4x annual EBITDA, reflecting thinner margins combined with prescription file and inventory value.
Yes, significantly. Monthly prescription count is the core driver of revenue, and buyers weigh script volume trends heavily.
Yes. A favorable mix of commercial insurance and cash-pay prescriptions relative to government plans typically supports a stronger valuation.
Declining prescription volume, an unfavorable payer mix, nearby chain competition, and outdated technology are the most common reasons a pharmacy sells below its potential.
I'll review your script volume, payer mix, and financials to give you a real valuation range — no cost, no obligation.